Format

Send to

Choose Destination
Nat Rev Cancer. 2007 May;7(5):332-44.

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

Author information

1
Center for Translational Medicine and Cardiology Division, Department of Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA. thomas.force@jefferson.edu

Abstract

Cancer therapy has progressed remarkably in recent years. In no area has this been more apparent than in the development of "targeted therapies", particularly those using drugs that inhibit the activity of certain tyrosine kinases, activating mutations or amplifications of which are causal, or strongly contributory, to tumorigenesis. However, some of these therapies have been associated with toxicity to the heart. Here we summarize what is known about the cardiotoxicity of cancer drugs that target tyrosine kinases. We focus on basic mechanisms through which interruption of specific signalling pathways leads to cardiomyocyte dysfunction and/or death, and contrast this with therapeutic responses in cancer cells.

PMID:
17457301
DOI:
10.1038/nrc2106
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for eScholarship, California Digital Library, University of California
Loading ...
Support Center